| In the field of cancer, genetic mutations in the tumour can predict a response to oncology drugs. Tumour mutation analysis is technically challenging because of the heterogeneity of the sample. In practice this means that tumour mutation tests must be able to detect mutations even when the majority of the sample is not mutated.
DxS has an oncology test panel that uses ARMS technology, which allows for very sensitive tests that can detect mutations in background of normal cells. Mutations can be detected at a ratio of 1:100 mutant:normal DNA and this allows DxS to detect genetic variation that could not be seen using DNA sequencing methods. This is very valuable in an oncology clinical trial because it can improve the accuracy of detection and allow a better correlation between mutation, prognosis and drug response. We have a panel of tests for detecting mutations in: - EGFR (including T790M)
- K-RAS
- B-RAF
| |  | |